[{"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-001", "question": "A 52-year-old woman with primary sclerosing cholangitis and ulcerative colitis presents with progressive fatigue and pruritus. Laboratory studies show alkaline phosphatase 892 U/L, total bilirubin 4.2 mg/dL, and CA 19-9 of 285 U/mL. MRCP reveals a dominant stricture at the hepatic duct bifurcation with upstream biliary dilation. Brush cytology obtained during ERCP shows atypical cells suspicious for malignancy. Fluorescence in situ hybridization (FISH) analysis demonstrates polysomy. Which additional finding on FISH would most strongly support a diagnosis of cholangiocarcinoma over reactive atypia in this clinical context?", "options": ["Homozygous deletion of 9p21 (CDKN2A/p16)", "Trisomy of chromosome 7", "Monosomy of chromosome 17", "Gain of chromosome 3", "Deletion of 1p36"], "answer": "A", "answer_index": 0, "explanation": "Homozygous deletion of 9p21 (CDKN2A/p16) detected by FISH has the highest specificity (approaching 100%) for cholangiocarcinoma in the setting of PSC with indeterminate biliary strictures. While polysomy alone increases suspicion for malignancy, it can occur in reactive conditions. Trisomy 7 and other chromosomal gains are less specific. The combination of polysomy plus 9p21 homozygous deletion essentially confirms malignancy in this high-risk population.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: PSC plus UC (high-risk setting), dominant hilar stricture with upstream dilation, markedly elevated CA 19-9, ERCP brushings with atypical cells and FISH polysomy. Question asks which *additional* FISH abnormality would most strongly favor cholangiocarcinoma vs reactive atypia. In PSC-related indeterminate strictures, homozygous deletion of 9p21 (CDKN2A/p16) on FISH is well-described as highly specific (near 100%) for cholangiocarcinoma when present, especially in combination with polysomy. Trisomy 7 or other single-chromosome gains (choices B, D) are more common and less specific for malignancy. Monosomy 17 (C) and 1p36 deletion (E) are not characteristic hallmark changes for PSC-associated cholangiocarcinoma and are not established as the most specific markers in this context.\\nMain logical issues: None; the stem clearly frames a single best answer based on known FISH markers in PSC strictures. No internal contradictions or underspecification.\\nMain medical accuracy issues: None significant; teaching point matches hepatobiliary pathology literature.\\nMinimal fix: Optionally add a brief parenthetical in the explanation citing that 9p21 homozygous deletion plus polysomy is considered essentially diagnostic in PSC-related indeterminate strictures to reinforce evidence basis.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: PSC plus UC (high-risk setting), dominant hilar stricture with upstream dilation, markedly elevated CA 19-9, ERCP brushings with atypical cells and FISH polysomy. Question asks which *additional* FISH abnormality would most strongly favor cholangiocarcinoma vs reactive atypia. In PSC-related indeterminate strictures, homozygous deletion of 9p21 (CDKN2A/p16) on FISH is well-described as highly specific (near 100%) for cholangiocarcinoma when present, especially in combination with polysomy. Trisomy 7 or other single-chromosome gains (choices B, D) are more common and less specific for malignancy. Monosomy 17 (C) and 1p36 deletion (E) are not characteristic hallmark changes for PSC-associated cholangiocarcinoma and are not established as the most specific markers in this context.\nMain logical issues: None; the stem clearly frames a single best answer based on known FISH markers in PSC strictures. No internal contradictions or underspecification.\nMain medical accuracy issues: None significant; teaching point matches hepatobiliary pathology literature.\nMinimal fix: Optionally add a brief parenthetical in the explanation citing that 9p21 homozygous deletion plus polysomy is considered essentially diagnostic in PSC-related indeterminate strictures to reinforce evidence basis.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-002", "question": "A 38-year-old man undergoes evaluation for chronic diarrhea and weight loss. Small bowel biopsy reveals villous atrophy with increased intraepithelial lymphocytes. Despite strict gluten-free diet adherence confirmed by negative tissue transglutaminase antibodies for 18 months, symptoms persist. Repeat biopsy shows persistent villous atrophy with aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, and CD103, with loss of CD8. T-cell receptor gene rearrangement studies show a monoclonal population. Which therapeutic approach offers the best chance of inducing remission before consideration of autologous stem cell transplantation?", "options": ["Budesonide 9 mg daily", "Cladribine-based chemotherapy", "Infliximab induction and maintenance", "Azathioprine 2.5 mg/kg daily", "Mesalamine 4.8 g daily"], "answer": "B", "answer_index": 1, "explanation": "This patient has Type II refractory celiac disease (RCD II), characterized by aberrant intraepithelial lymphocytes with the described immunophenotype (surface CD3-negative, cytoplasmic CD3-positive, CD8 loss) and monoclonal TCR rearrangement. RCD II has high risk of progression to enteropathy-associated T-cell lymphoma. Cladribine (2-CdA), a purine analog, has shown the best response rates (approximately 40-50%) in inducing histologic and clinical remission in RCD II and serves as a bridge to autologous stem cell transplantation. Steroids, immunomodulators, and biologics used in RCD I are ineffective in RCD II.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Persistent diarrhea and villous atrophy despite 18 months of well-documented gluten-free diet (negative tTG), small-bowel biopsy with villous atrophy and aberrant intraepithelial lymphocytes lacking surface CD3, expressing cytoplasmic CD3, CD7, CD103, with loss of CD8, and monoclonal TCR rearrangement. These findings define type II refractory celiac disease (RCD II), a clonal, pre-lymphomatous condition with high risk of enteropathy-associated T-cell lymphoma.\\nOption B (cladribine-based chemotherapy) is consistent with current specialized management of RCD II, where purine analogs such as 2-CdA are used to induce remission and as a bridge to autologous stem cell transplantation. Budesonide, azathioprine, mesalamine, and infliximab are more appropriate for RCD I or other inflammatory conditions and have poor efficacy in RCD II, so they are clearly inferior choices.\\nNo major logical or medical inaccuracies are present; the immunophenotype and management hierarchy are accurate for board-level expectations.\\nMinimal fix: Clarify in the stem that evaluation has excluded other causes of villous atrophy (e.g., infections, medications, common variable immunodeficiency) to reinforce that this is true refractory celiac disease type II rather than another etiology.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Persistent diarrhea and villous atrophy despite 18 months of well-documented gluten-free diet (negative tTG), small-bowel biopsy with villous atrophy and aberrant intraepithelial lymphocytes lacking surface CD3, expressing cytoplasmic CD3, CD7, CD103, with loss of CD8, and monoclonal TCR rearrangement. These findings define type II refractory celiac disease (RCD II), a clonal, pre-lymphomatous condition with high risk of enteropathy-associated T-cell lymphoma.\nOption B (cladribine-based chemotherapy) is consistent with current specialized management of RCD II, where purine analogs such as 2-CdA are used to induce remission and as a bridge to autologous stem cell transplantation. Budesonide, azathioprine, mesalamine, and infliximab are more appropriate for RCD I or other inflammatory conditions and have poor efficacy in RCD II, so they are clearly inferior choices.\nNo major logical or medical inaccuracies are present; the immunophenotype and management hierarchy are accurate for board-level expectations.\nMinimal fix: Clarify in the stem that evaluation has excluded other causes of villous atrophy (e.g., infections, medications, common variable immunodeficiency) to reinforce that this is true refractory celiac disease type II rather than another etiology.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-003", "question": "A 45-year-old woman with lupus nephritis class IV on mycophenolate mofetil and prednisone develops acute kidney injury with serum creatinine rising from 1.2 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous dysmorphic RBCs, and RBC casts. Complement levels are normal and anti-dsDNA titers are stable. Kidney biopsy reveals crescentic glomerulonephritis with linear IgG staining along the glomerular basement membrane, with concurrent immune complex deposits in the mesangium. Anti-GBM antibodies are positive at 85 EU (normal <20). Which statement best characterizes this clinical entity?", "options": ["This represents lupus flare requiring intensification of immunosuppression alone", "The linear IgG staining is an artifact from prior immune complex deposition", "This is anti-GBM disease superimposed on lupus nephritis requiring plasmapheresis", "Concurrent ANCA-associated vasculitis is the most likely explanation", "The anti-GBM antibodies are false-positive due to cross-reactivity with dsDNA"], "answer": "C", "answer_index": 2, "explanation": "This patient has developed anti-GBM disease superimposed on pre-existing lupus nephritis, a rare but well-documented phenomenon. The linear IgG staining pattern is pathognomonic for anti-GBM disease and distinct from the granular pattern of lupus nephritis. The presence of positive anti-GBM antibodies confirms the diagnosis. Treatment requires plasmapheresis to remove circulating anti-GBM antibodies in addition to immunosuppression. Normal complements and stable anti-dsDNA argue against lupus flare as the sole explanation. Anti-GBM antibodies target the NC1 domain of type IV collagen and do not cross-react with dsDNA.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known class IV lupus nephritis on MMF + prednisone; rapid AKI with active urinary sediment; biopsy showing crescentic GN with linear IgG along GBM plus immune-complex mesangial deposits; clearly positive anti-GBM antibodies; normal complement and stable anti-dsDNA. These strongly indicate anti-GBM disease superimposed on pre-existing lupus nephritis (“dual glomerulopathy”), for which plasmapheresis is standard.\\nOption analysis: A is weaker because normal complement and stable dsDNA argue against isolated lupus flare; histology shows linear, not purely granular, staining and positive anti-GBM serology. B is incorrect: linear IgG is not an artifact and is pathognomonic for anti-GBM disease. C correctly identifies anti-GBM disease superimposed on lupus requiring plasmapheresis. D is unsupported: no ANCA data and biopsy shows linear IgG, not pauci-immune GN. E is incorrect: anti-GBM Abs target type IV collagen NC1 domain and do not cross-react with dsDNA; positive result fits the pathology.\\nMain medical issues: None; content is accurate and up to date.\\nMinimal fix: Option D could be reworded to include ANCA positivity to make it clearly incorrect (or add a stem statement that ANCA testing is negative).\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known class IV lupus nephritis on MMF + prednisone; rapid AKI with active urinary sediment; biopsy showing crescentic GN with linear IgG along GBM plus immune-complex mesangial deposits; clearly positive anti-GBM antibodies; normal complement and stable anti-dsDNA. These strongly indicate anti-GBM disease superimposed on pre-existing lupus nephritis (“dual glomerulopathy”), for which plasmapheresis is standard.\nOption analysis: A is weaker because normal complement and stable dsDNA argue against isolated lupus flare; histology shows linear, not purely granular, staining and positive anti-GBM serology. B is incorrect: linear IgG is not an artifact and is pathognomonic for anti-GBM disease. C correctly identifies anti-GBM disease superimposed on lupus requiring plasmapheresis. D is unsupported: no ANCA data and biopsy shows linear IgG, not pauci-immune GN. E is incorrect: anti-GBM Abs target type IV collagen NC1 domain and do not cross-react with dsDNA; positive result fits the pathology.\nMain medical issues: None; content is accurate and up to date.\nMinimal fix: Option D could be reworded to include ANCA positivity to make it clearly incorrect (or add a stem statement that ANCA testing is negative).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-004", "question": "A 62-year-old man with myelodysplastic syndrome with excess blasts-2 (MDS-EB2) undergoes allogeneic hematopoietic stem cell transplantation from a matched unrelated donor. On day +45, he develops progressive pancytopenia with WBC 0.8 × 10⁹/L, hemoglobin 7.2 g/dL, and platelets 12 × 10⁹/L. Bone marrow biopsy shows hypocellularity (10%) with no evidence of relapsed MDS. Chimerism analysis reveals 100% donor cells. Cytomegalovirus and HHV-6 PCR are negative. Which mechanism most likely explains this patient's graft failure?", "options": ["Donor-derived clonal hematopoiesis with DDX41 germline mutation", "Secondary hemophagocytic lymphohistiocytosis", "Graft-versus-host disease affecting the bone marrow stroma", "Residual host T-cell mediated rejection despite full donor chimerism", "Drug-induced marrow suppression from valganciclovir prophylaxis"], "answer": "A", "answer_index": 0, "explanation": "Donor-derived clonal hematopoiesis from germline mutations (particularly DDX41) in the donor can cause graft failure or donor-derived MDS/AML post-transplant. DDX41 mutations are increasingly recognized as a cause of familial MDS/AML and can be present in phenotypically normal donors. The 100% donor chimerism excludes host-mediated rejection. The absence of CMV/HHV-6 and the clinical context make drug toxicity less likely. HLH would typically show additional features (ferritin elevation, hepatosplenomegaly). Marrow stromal GVHD is rare and would not explain isolated hematopoietic failure with full donor chimerism.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N\\nVerdict on keyed answer: No defensible answer (A is not supported by the stem as a “most likely” mechanism)\\nKey stem clues: Day +45 post–allogeneic HSCT, progressive pancytopenia, markedly hypocellular marrow (10%), no relapsed MDS, 100% donor chimerism, negative CMV/HHV-6. Clinical question: mechanism of early graft failure/aplasia despite full donor chimerism.\\nMain logical issues: The stem does not provide any data suggesting donor-derived clonal hematopoiesis or DDX41 germline mutation (no prior donor history, family history, cytogenetics, or morphology compatible with donor-derived MDS/AML). Moreover, donor-derived MDS/AML or clonal hematopoiesis generally presents later post-transplant, not by day +45 with pure aplasia. Thus, A is speculative, not “most likely.” Other listed mechanisms (e.g., drug toxicity, immune causes) are also poorly supported or imperfect, so none is clearly defensible as best; early poor graft function/aplasia mechanisms are incompletely represented in the choices.\\nMain medical accuracy issues: The pathophysiologic description of DDX41 is accurate, but timing and presentation here are incongruent. Several distractors are vaguely framed (e.g., marrow stromal GVHD) and not clearly excludable from the sparse data.\\nMinimal fix: Add specific data implicating a DDX41-mutated donor (known familial mutation, donor sequencing) and/or change timing to late post-transplant to justify A as most likely.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N\nVerdict on keyed answer: No defensible answer (A is not supported by the stem as a “most likely” mechanism)\nKey stem clues: Day +45 post–allogeneic HSCT, progressive pancytopenia, markedly hypocellular marrow (10%), no relapsed MDS, 100% donor chimerism, negative CMV/HHV-6. Clinical question: mechanism of early graft failure/aplasia despite full donor chimerism.\nMain logical issues: The stem does not provide any data suggesting donor-derived clonal hematopoiesis or DDX41 germline mutation (no prior donor history, family history, cytogenetics, or morphology compatible with donor-derived MDS/AML). Moreover, donor-derived MDS/AML or clonal hematopoiesis generally presents later post-transplant, not by day +45 with pure aplasia. Thus, A is speculative, not “most likely.” Other listed mechanisms (e.g., drug toxicity, immune causes) are also poorly supported or imperfect, so none is clearly defensible as best; early poor graft function/aplasia mechanisms are incompletely represented in the choices.\nMain medical accuracy issues: The pathophysiologic description of DDX41 is accurate, but timing and presentation here are incongruent. Several distractors are vaguely framed (e.g., marrow stromal GVHD) and not clearly excludable from the sparse data.\nMinimal fix: Add specific data implicating a DDX41-mutated donor (known familial mutation, donor sequencing) and/or change timing to late post-transplant to justify A as most likely.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-005", "question": "A 28-year-old woman presents with recurrent sinopulmonary infections since childhood, chronic diarrhea, and splenomegaly. Laboratory evaluation reveals IgG 180 mg/dL (normal 700-1600), IgA <7 mg/dL, IgM 320 mg/dL (normal 40-230), and absent isohemagglutinins. Flow cytometry shows normal B-cell numbers but absent CD27+ memory B cells. Genetic testing reveals a hemizygous mutation in CD40LG. Her brother has similar symptoms. Which finding would be most unexpected in this patient?", "options": ["Cryptosporidium parvum cholangiopathy", "Pneumocystis jirovecii pneumonia", "Germinal center formation on lymph node biopsy", "Neutropenia", "Elevated liver enzymes"], "answer": "C", "answer_index": 2, "explanation": "This patient has X-linked hyper-IgM syndrome (HIGM1) due to CD40LG mutation, which can occur in females due to skewed X-inactivation or homozygosity. CD40L-CD40 interaction is essential for germinal center formation, class-switch recombination, and somatic hypermutation. Therefore, germinal center formation would be absent on lymph node biopsy. Cryptosporidium cholangiopathy, PCP, neutropenia (due to impaired granulopoiesis), and elevated liver enzymes (from sclerosing cholangitis or hepatitis) are all well-documented complications of HIGM1.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recurrent sinopulmonary infections, chronic diarrhea, splenomegaly; very low IgG and IgA with elevated/normal IgM; absent isohemagglutinins; normal B-cell numbers but absent CD27+ memory B cells; hemizygous CD40LG mutation; affected brother. These define X-linked hyper-IgM syndrome (HIGM1, CD40L deficiency), a combined immunodeficiency with defective class-switching and germinal center formation.\\nIn CD40L deficiency, CD40–CD40L interaction is required for germinal center formation, so intact germinal centers on lymph node biopsy would be unexpected, making option C the single best answer. The other options are known or plausible complications: Cryptosporidium parvum cholangiopathy and elevated liver enzymes from sclerosing cholangitis/hepatitis; Pneumocystis jirovecii pneumonia from T-cell functional defect; neutropenia due to impaired granulopoiesis/infections. The explanation’s comment on female presentation via skewed X-inactivation is unusual but biologically plausible and not central to the item’s logic.\\nMain medical accuracy issues: minor—HIGM1 classically presents in males, but a symptomatic heterozygous female is possible. Minimal fix: Clarify in the stem that she is a symptomatic carrier with skewed X-inactivation or simply make the patient male to match classic teaching.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recurrent sinopulmonary infections, chronic diarrhea, splenomegaly; very low IgG and IgA with elevated/normal IgM; absent isohemagglutinins; normal B-cell numbers but absent CD27+ memory B cells; hemizygous CD40LG mutation; affected brother. These define X-linked hyper-IgM syndrome (HIGM1, CD40L deficiency), a combined immunodeficiency with defective class-switching and germinal center formation.\nIn CD40L deficiency, CD40–CD40L interaction is required for germinal center formation, so intact germinal centers on lymph node biopsy would be unexpected, making option C the single best answer. The other options are known or plausible complications: Cryptosporidium parvum cholangiopathy and elevated liver enzymes from sclerosing cholangitis/hepatitis; Pneumocystis jirovecii pneumonia from T-cell functional defect; neutropenia due to impaired granulopoiesis/infections. The explanation’s comment on female presentation via skewed X-inactivation is unusual but biologically plausible and not central to the item’s logic.\nMain medical accuracy issues: minor—HIGM1 classically presents in males, but a symptomatic heterozygous female is possible. Minimal fix: Clarify in the stem that she is a symptomatic carrier with skewed X-inactivation or simply make the patient male to match classic teaching.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-006", "question": "A 34-year-old man from the Ohio River Valley presents with 3 weeks of fever, night sweats, and 15-pound weight loss. He has a history of HIV infection with CD4 count of 45 cells/μL and is not on antiretroviral therapy. Physical examination reveals hepatosplenomegaly and diffuse lymphadenopathy. Laboratory studies show pancytopenia and LDH 1,850 U/L. Bone marrow biopsy reveals small intracellular yeast forms within macrophages. Urine Histoplasma antigen is strongly positive. He is started on liposomal amphotericin B. On day 3 of treatment, he develops high fever, hypotension, and worsening respiratory status despite negative blood cultures and improving fungal markers. Which intervention is most appropriate?", "options": ["Add voriconazole for possible amphotericin-resistant Histoplasma", "Initiate corticosteroids for immune reconstitution inflammatory syndrome", "Switch to itraconazole due to amphotericin B toxicity", "Add broad-spectrum antibiotics for bacterial superinfection", "Delay antiretroviral therapy initiation for at least 4 weeks"], "answer": "B", "answer_index": 1, "explanation": "This patient is experiencing paradoxical worsening consistent with immune reconstitution inflammatory syndrome (IRIS), which can occur in severely immunocompromised HIV patients even before ART initiation (unmasking IRIS) or represent early inflammatory response to effective antifungal therapy. The improving fungal markers argue against treatment failure or resistance. Corticosteroids (prednisone 0.5-1 mg/kg) are the treatment of choice for moderate-to-severe IRIS. While ART timing is important, the immediate management of IRIS takes precedence. Amphotericin B resistance in Histoplasma is exceedingly rare.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (with elements of U). Verdict on keyed answer: No defensible answer; item’s premise is medically incorrect. Key stem clues: Advanced HIV (CD4 45), disseminated histoplasmosis (intracellular yeasts in macrophages, positive urine antigen), started on liposomal amphotericin B; by day 3 has high fever, hypotension, and worsening respiratory status, with negative cultures and improving fungal markers. Question asks for most appropriate intervention. Major logical/medical issue: The explanation claims this is immune reconstitution inflammatory syndrome (IRIS) and that IRIS can occur before ART initiation in this context. Classic IRIS in HIV requires recent immune recovery, almost always following ART initiation or withdrawal of immunosuppression; it does not occur de novo 3 days after starting amphotericin in a patient who remains severely immunocompromised and is off ART. Thus option B is not medically defensible. Other options are also problematic or require more data, so no option is clearly correct. Minimal fix: Explicitly state that ART was initiated 1–2 weeks prior and CD4/viral load are improving, and adjust the explanation to standard HIV-associated IRIS; then B could become defensible, or alternatively change the keyed answer to E with appropriate timing details for ART initiation in severe histoplasmosis.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (with elements of U). Verdict on keyed answer: No defensible answer; item’s premise is medically incorrect. Key stem clues: Advanced HIV (CD4 45), disseminated histoplasmosis (intracellular yeasts in macrophages, positive urine antigen), started on liposomal amphotericin B; by day 3 has high fever, hypotension, and worsening respiratory status, with negative cultures and improving fungal markers. Question asks for most appropriate intervention. Major logical/medical issue: The explanation claims this is immune reconstitution inflammatory syndrome (IRIS) and that IRIS can occur before ART initiation in this context. Classic IRIS in HIV requires recent immune recovery, almost always following ART initiation or withdrawal of immunosuppression; it does not occur de novo 3 days after starting amphotericin in a patient who remains severely immunocompromised and is off ART. Thus option B is not medically defensible. Other options are also problematic or require more data, so no option is clearly correct. Minimal fix: Explicitly state that ART was initiated 1–2 weeks prior and CD4/viral load are improving, and adjust the explanation to standard HIV-associated IRIS; then B could become defensible, or alternatively change the keyed answer to E with appropriate timing details for ART initiation in severe histoplasmosis.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-007", "question": "A 58-year-old woman with metastatic HER2-positive breast cancer on trastuzumab deruxtecan develops progressive dyspnea over 4 weeks. CT chest reveals bilateral ground-glass opacities with a peripheral and lower lobe predominant distribution. Bronchoalveolar lavage shows lymphocytic predominance with CD4/CD8 ratio of 0.5. Infectious workup is negative. She is diagnosed with drug-induced interstitial lung disease. After drug discontinuation and corticosteroid initiation, her symptoms improve. Three months later, restaging shows disease progression. Which factor most strongly supports rechallenge with trastuzumab deruxtecan?", "options": ["Initial ILD grade was 1 with complete radiographic resolution", "Absence of anti-drug antibodies on serologic testing", "HER2 amplification ratio >6 on repeat biopsy", "Negative rechallenge skin testing to the drug", "Normal pulmonary function tests at baseline before rechallenge"], "answer": "A", "answer_index": 0, "explanation": "Rechallenge with trastuzumab deruxtecan after ILD is a complex decision. Per consensus guidelines, rechallenge may be considered only in patients who experienced Grade 1 ILD that completely resolved both clinically and radiographically. Higher grade ILD (Grade 2-4) is generally considered a contraindication to rechallenge. Anti-drug antibodies, HER2 status, skin testing, and baseline PFTs do not reliably predict ILD recurrence risk. The mechanism of T-DXd-associated ILD is not fully understood but appears related to the topoisomerase I inhibitor payload rather than immune-mediated hypersensitivity.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Metastatic HER2+ breast cancer on trastuzumab deruxtecan; developed drug-induced ILD with classic imaging and BAL findings; improved after drug discontinuation and corticosteroids; now has disease progression 3 months later; question asks which factor most strongly supports rechallenge. Current consensus for T-DXd–associated ILD allows rechallenge only after Grade 1 ILD with complete clinical and radiographic resolution; Grade ≥2 ILD is a contraindication.\\nOption A exactly encodes this guideline criterion, making it the single best answer. Options B–E either lack evidence of predictive value for ILD recurrence (anti-drug antibodies, skin testing, HER2 amplification) or are necessary but not sufficient conditions that do not specifically support safety of rechallenge (normal baseline PFTs). Thus only A directly addresses the pivotal safety requirement.\\nMain logical issue(s): None; stem clearly points to guideline-based criterion, and alternatives are plausibly incorrect.\\nMain medical accuracy issues: None significant; description of T-DXd ILD management and mechanism is consistent with contemporary recommendations.\\nMinimal fix: Specify the ILD was clearly Grade 1 in the vignette (rather than only in the answer choice) to more tightly link stem and correct option, though not strictly necessary for solvability.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Metastatic HER2+ breast cancer on trastuzumab deruxtecan; developed drug-induced ILD with classic imaging and BAL findings; improved after drug discontinuation and corticosteroids; now has disease progression 3 months later; question asks which factor most strongly supports rechallenge. Current consensus for T-DXd–associated ILD allows rechallenge only after Grade 1 ILD with complete clinical and radiographic resolution; Grade ≥2 ILD is a contraindication.\nOption A exactly encodes this guideline criterion, making it the single best answer. Options B–E either lack evidence of predictive value for ILD recurrence (anti-drug antibodies, skin testing, HER2 amplification) or are necessary but not sufficient conditions that do not specifically support safety of rechallenge (normal baseline PFTs). Thus only A directly addresses the pivotal safety requirement.\nMain logical issue(s): None; stem clearly points to guideline-based criterion, and alternatives are plausibly incorrect.\nMain medical accuracy issues: None significant; description of T-DXd ILD management and mechanism is consistent with contemporary recommendations.\nMinimal fix: Specify the ILD was clearly Grade 1 in the vignette (rather than only in the answer choice) to more tightly link stem and correct option, though not strictly necessary for solvability.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-008", "question": "A 42-year-old woman with a history of chronic rhinosinusitis and nasal polyps presents with new-onset asthma requiring systemic corticosteroids. She reports severe reactions to aspirin and ibuprofen characterized by bronchospasm and nasal congestion. She requires hip replacement surgery and the orthopedic surgeon requests clearance for perioperative ketorolac use. After shared decision-making, aspirin desensitization is planned. During the desensitization protocol, she develops bronchospasm at the 60 mg aspirin dose. Which mediator's urinary metabolite would be most elevated during this reaction?", "options": ["Leukotriene E4", "Prostaglandin D2 (as 11β-prostaglandin F2α)", "Histamine (as N-methylhistamine)", "Tryptase", "Platelet-activating factor"], "answer": "A", "answer_index": 0, "explanation": "Aspirin-exacerbated respiratory disease (AERD) is characterized by overproduction of cysteinyl leukotrienes (CysLTs) due to dysregulated arachidonic acid metabolism. During aspirin-induced reactions in AERD, urinary leukotriene E4 (LTE4), the stable end-metabolite of CysLTs, increases dramatically (often 3-10 fold). This distinguishes AERD from IgE-mediated reactions where prostaglandin D2 metabolites and histamine metabolites predominate. Tryptase elevation suggests mast cell degranulation in anaphylaxis but is not characteristic of AERD reactions. The CysLT pathway is the primary driver of bronchoconstriction in AERD.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Chronic rhinosinusitis with nasal polyps, adult-onset corticosteroid-requiring asthma, and respiratory reactions to aspirin/NSAIDs define aspirin‑exacerbated respiratory disease (AERD). The question asks which mediator’s urinary metabolite is most elevated during an aspirin desensitization reaction at 60 mg, i.e., during active aspirin-induced bronchospasm in AERD.\\nIn AERD, inhibition of COX-1 shunts arachidonic acid toward the 5‑lipoxygenase pathway, causing marked overproduction of cysteinyl leukotrienes. Leukotriene E4 (LTE4) is the stable end-metabolite excreted in urine and is known to rise several-fold during aspirin reactions in AERD, making option A the single best answer.\\nOption B: PGD2 metabolites can increase with mast-cell activation but are not the dominant, characteristic urinary marker in AERD. C and D (histamine and tryptase) are markers of classic IgE-mediated anaphylaxis, which the stem explicitly contrasts with AERD. E (platelet-activating factor) is implicated in anaphylaxis severity but is not the defining elevated urinary metabolite here. No internal contradictions or underspecification are present.\\nMinimal fix: None required; item is already clear and accurate. Minor optional improvement: specify “urinary metabolite most characteristically and markedly elevated in AERD reactions.”\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Chronic rhinosinusitis with nasal polyps, adult-onset corticosteroid-requiring asthma, and respiratory reactions to aspirin/NSAIDs define aspirin‑exacerbated respiratory disease (AERD). The question asks which mediator’s urinary metabolite is most elevated during an aspirin desensitization reaction at 60 mg, i.e., during active aspirin-induced bronchospasm in AERD.\nIn AERD, inhibition of COX-1 shunts arachidonic acid toward the 5‑lipoxygenase pathway, causing marked overproduction of cysteinyl leukotrienes. Leukotriene E4 (LTE4) is the stable end-metabolite excreted in urine and is known to rise several-fold during aspirin reactions in AERD, making option A the single best answer.\nOption B: PGD2 metabolites can increase with mast-cell activation but are not the dominant, characteristic urinary marker in AERD. C and D (histamine and tryptase) are markers of classic IgE-mediated anaphylaxis, which the stem explicitly contrasts with AERD. E (platelet-activating factor) is implicated in anaphylaxis severity but is not the defining elevated urinary metabolite here. No internal contradictions or underspecification are present.\nMinimal fix: None required; item is already clear and accurate. Minor optional improvement: specify “urinary metabolite most characteristically and markedly elevated in AERD reactions.”", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-009", "question": "An 82-year-old woman with moderate Alzheimer's dementia (MMSE 18) living in assisted living is hospitalized for community-acquired pneumonia. On hospital day 2, she becomes acutely agitated with visual hallucinations. Her medications include donepezil, memantine, and lisinopril. She is started on haloperidol 0.5 mg for agitation. On day 3, she develops temperature 39.2°C, severe muscle rigidity, diaphoresis, and altered consciousness. Laboratory studies show CK 8,500 U/L and WBC 14,000/μL. Which mechanism best explains this presentation?", "options": ["Anticholinergic toxicity from haloperidol-donepezil interaction", "Dopamine receptor blockade causing neuroleptic malignant syndrome", "Serotonin syndrome from memantine-haloperidol interaction", "Malignant hyperthermia triggered by infection", "Central fever from hypothalamic involvement by infection"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed neuroleptic malignant syndrome (NMS) following haloperidol administration, characterized by the classic tetrad of hyperthermia, severe rigidity, altered mental status, and autonomic instability with elevated CK. Elderly patients with dementia are at increased risk for NMS. The mechanism is dopamine D2 receptor blockade in the hypothalamus and nigrostriatal pathways. While donepezil increases acetylcholine (potentially worsening extrapyramidal symptoms), the presentation is classic for NMS rather than anticholinergic toxicity. Memantine is an NMDA antagonist with minimal serotonergic activity, making serotonin syndrome unlikely.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent initiation of haloperidol; acute onset of hyperthermia (39.2°C), severe muscle rigidity, diaphoresis, altered consciousness; markedly elevated CK (8,500 U/L) and leukocytosis following antipsychotic use. These findings are classic for neuroleptic malignant syndrome (NMS). The mechanism is central dopamine D2 receptor blockade, especially in hypothalamic and nigrostriatal pathways.\\nOption analysis: (A) Anticholinergic toxicity typically causes dry mucous membranes, urinary retention, mydriasis, decreased bowel sounds, and not severe rigidity with very high CK. (B) Correct: describes NMS mechanism. (C) Serotonin syndrome usually involves hyperreflexia, clonus, mydriasis, and serotonergic drugs; memantine has minimal serotonergic activity and haloperidol is not serotonergic. (D) Malignant hyperthermia is associated with volatile anesthetics or succinylcholine, not haloperidol in a medical ward. (E) Central fever would not explain severe rigidity and extreme CK elevation.\\nMain medical accuracy issues: None; associations and mechanisms match standard teaching. Age, dementia, and antipsychotic use as risk factors are plausible. \\nMinimal fix: None required; item is already unambiguous and accurate. Option A could be rephrased to ‘cholinergic effects’ to avoid the term ‘anticholinergic toxicity,’ but this does not affect correctness.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent initiation of haloperidol; acute onset of hyperthermia (39.2°C), severe muscle rigidity, diaphoresis, altered consciousness; markedly elevated CK (8,500 U/L) and leukocytosis following antipsychotic use. These findings are classic for neuroleptic malignant syndrome (NMS). The mechanism is central dopamine D2 receptor blockade, especially in hypothalamic and nigrostriatal pathways.\nOption analysis: (A) Anticholinergic toxicity typically causes dry mucous membranes, urinary retention, mydriasis, decreased bowel sounds, and not severe rigidity with very high CK. (B) Correct: describes NMS mechanism. (C) Serotonin syndrome usually involves hyperreflexia, clonus, mydriasis, and serotonergic drugs; memantine has minimal serotonergic activity and haloperidol is not serotonergic. (D) Malignant hyperthermia is associated with volatile anesthetics or succinylcholine, not haloperidol in a medical ward. (E) Central fever would not explain severe rigidity and extreme CK elevation.\nMain medical accuracy issues: None; associations and mechanisms match standard teaching. Age, dementia, and antipsychotic use as risk factors are plausible. \nMinimal fix: None required; item is already unambiguous and accurate. Option A could be rephrased to ‘cholinergic effects’ to avoid the term ‘anticholinergic toxicity,’ but this does not affect correctness.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-010", "question": "A 55-year-old man with cirrhosis secondary to alcohol use disorder and hepatocellular carcinoma (single 3.5 cm lesion, no vascular invasion, AFP 450 ng/mL) undergoes liver transplantation. Explant pathology confirms a single 3.8 cm moderately differentiated HCC without microvascular invasion. Eighteen months post-transplant, surveillance imaging reveals a 2.2 cm lung nodule. Biopsy confirms metastatic HCC. His current immunosuppression includes tacrolimus and mycophenolate mofetil. Which modification to his immunosuppressive regimen is most strongly supported by evidence for managing this recurrence?", "options": ["Conversion from tacrolimus to cyclosporine", "Addition of belatacept to current regimen", "Conversion from tacrolimus to sirolimus", "Discontinuation of all immunosuppression", "Addition of azathioprine to current regimen"], "answer": "C", "answer_index": 2, "explanation": "Conversion from calcineurin inhibitors (tacrolimus) to mTOR inhibitors (sirolimus/everolimus) is recommended in post-transplant HCC recurrence. mTOR inhibitors have direct antitumor effects through inhibition of the PI3K/AKT/mTOR pathway, which is frequently dysregulated in HCC. Multiple studies have shown improved outcomes with mTOR inhibitor-based immunosuppression in HCC recurrence. Complete immunosuppression withdrawal risks allograft rejection without proven oncologic benefit. Cyclosporine, belatacept, and azathioprine lack the antitumor properties of mTOR inhibitors.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Post–liver transplant patient for HCC, now with biopsy-proven metastatic HCC at 18 months; currently on tacrolimus + mycophenolate. Question asks specifically for the immunosuppression modification best supported by evidence in this context.\\nThe clinical issue is optimization of immunosuppression in a liver-transplant recipient with recurrent/metastatic HCC. Evidence (cohort data and meta-analyses) supports switching from calcineurin inhibitors (CNIs) to an mTOR inhibitor (sirolimus or everolimus) to reduce tumor-promoting effects of CNIs and leverage potential antitumor effects of mTOR inhibition, with better recurrence-free and sometimes overall survival in HCC transplant cohorts.\\nOption C (conversion from tacrolimus to sirolimus) aligns with this rationale. \\nOther options: A (tacrolimus → cyclosporine) simply substitutes one CNI for another, with no antitumor benefit and possible worse oncologic profile. B (add belatacept) is not standard in liver transplantation and has no proven HCC benefit. D (stop all immunosuppression) carries high rejection risk and no solid evidence for improved cancer control. E (add azathioprine) increases immunosuppression and malignancy risk without antitumor effect.\\nMinimal fix: Cite or allude to mTOR-inhibitor–based regimens (sirolimus/everolimus) as standard practice per major transplant guidelines to strengthen evidence framing.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Post–liver transplant patient for HCC, now with biopsy-proven metastatic HCC at 18 months; currently on tacrolimus + mycophenolate. Question asks specifically for the immunosuppression modification best supported by evidence in this context.\nThe clinical issue is optimization of immunosuppression in a liver-transplant recipient with recurrent/metastatic HCC. Evidence (cohort data and meta-analyses) supports switching from calcineurin inhibitors (CNIs) to an mTOR inhibitor (sirolimus or everolimus) to reduce tumor-promoting effects of CNIs and leverage potential antitumor effects of mTOR inhibition, with better recurrence-free and sometimes overall survival in HCC transplant cohorts.\nOption C (conversion from tacrolimus to sirolimus) aligns with this rationale. \nOther options: A (tacrolimus → cyclosporine) simply substitutes one CNI for another, with no antitumor benefit and possible worse oncologic profile. B (add belatacept) is not standard in liver transplantation and has no proven HCC benefit. D (stop all immunosuppression) carries high rejection risk and no solid evidence for improved cancer control. E (add azathioprine) increases immunosuppression and malignancy risk without antitumor effect.\nMinimal fix: Cite or allude to mTOR-inhibitor–based regimens (sirolimus/everolimus) as standard practice per major transplant guidelines to strengthen evidence framing.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-011", "question": "A 48-year-old woman with Crohn's disease on vedolizumab presents with 6 months of progressive fatigue, exertional dyspnea, and paresthesias in her feet. Laboratory studies reveal hemoglobin 8.2 g/dL, MCV 118 fL, reticulocyte count 1.2%, LDH 890 U/L, and indirect bilirubin 2.1 mg/dL. Peripheral smear shows macro-ovalocytes and hypersegmented neutrophils. Vitamin B12 level is 85 pg/mL (normal >200). Anti-intrinsic factor antibodies are negative. She has no history of gastric surgery. Upper endoscopy with gastric biopsy shows chronic atrophic gastritis with intestinal metaplasia but no Helicobacter pylori. Which additional finding would most strongly suggest an autoimmune etiology despite negative anti-IF antibodies?", "options": ["Elevated serum gastrin level >1000 pg/mL", "Presence of anti-parietal cell antibodies", "Low serum pepsinogen I with normal pepsinogen II", "Enterochromaffin-like cell hyperplasia on biopsy", "Positive anti-Saccharomyces cerevisiae antibodies"], "answer": "C", "answer_index": 2, "explanation": "Low serum pepsinogen I (PGI) with normal pepsinogen II (PGII), resulting in a low PGI/PGII ratio, is highly specific for corpus-predominant atrophic gastritis characteristic of autoimmune gastritis. PGI is produced exclusively by chief cells in the corpus, which are destroyed in autoimmune gastritis. Anti-IF antibodies have only 50-70% sensitivity for pernicious anemia. Anti-parietal cell antibodies are more sensitive but less specific. Elevated gastrin and ECL hyperplasia occur in autoimmune gastritis but are consequences rather than diagnostic markers. ASCA is associated with Crohn's disease, not autoimmune gastritis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Middle‑aged woman; clear B12 deficiency with megaloblastic anemia; chronic atrophic gastritis with intestinal metaplasia, no H. pylori; explicitly asking which additional finding would most strongly suggest an autoimmune etiology despite negative intrinsic factor antibodies. The focus is on a marker that is both specific and directly supportive of autoimmune corpus‑predominant atrophic gastritis.\\nOption C (low serum pepsinogen I with normal pepsinogen II) reflects selective loss of corpus/fundic chief cells, is highly specific for autoimmune corpus atrophic gastritis, and functions as a strong diagnostic marker, fitting the explanation and current evidence.\\nOptions A and D (hypergastrinemia and ECL cell hyperplasia) are indeed expected downstream consequences of achlorhydria in autoimmune gastritis, but they are less specific as they can occur in other causes of profound acid suppression (e.g., chronic PPI use, gastrinoma context for gastrin). Option B (anti‑parietal cell antibodies) is more sensitive but less specific than pepsinogen patterns; the stem asks for “most strongly suggest,” i.e., highest specificity. Option E is unrelated (Crohn’s marker).\\nMain medical accuracy issue(s): None significant; nuance about A/B/D is handled in explanation.\\nMinimal fix: Clarify in stem: “which additional serologic marker…” to emphasize biomarker focus over histologic changes.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Middle‑aged woman; clear B12 deficiency with megaloblastic anemia; chronic atrophic gastritis with intestinal metaplasia, no H. pylori; explicitly asking which additional finding would most strongly suggest an autoimmune etiology despite negative intrinsic factor antibodies. The focus is on a marker that is both specific and directly supportive of autoimmune corpus‑predominant atrophic gastritis.\nOption C (low serum pepsinogen I with normal pepsinogen II) reflects selective loss of corpus/fundic chief cells, is highly specific for autoimmune corpus atrophic gastritis, and functions as a strong diagnostic marker, fitting the explanation and current evidence.\nOptions A and D (hypergastrinemia and ECL cell hyperplasia) are indeed expected downstream consequences of achlorhydria in autoimmune gastritis, but they are less specific as they can occur in other causes of profound acid suppression (e.g., chronic PPI use, gastrinoma context for gastrin). Option B (anti‑parietal cell antibodies) is more sensitive but less specific than pepsinogen patterns; the stem asks for “most strongly suggest,” i.e., highest specificity. Option E is unrelated (Crohn’s marker).\nMain medical accuracy issue(s): None significant; nuance about A/B/D is handled in explanation.\nMinimal fix: Clarify in stem: “which additional serologic marker…” to emphasize biomarker focus over histologic changes.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-012", "question": "A 52-year-old man with IgA nephropathy and eGFR 35 mL/min/1.73m² is enrolled in a clinical trial evaluating a novel targeted-release formulation of budesonide (NEFECON). After 9 months of treatment, his 24-hour urine protein decreases from 2.8 g to 0.9 g, and eGFR stabilizes. Repeat kidney biopsy shows reduced mesangial IgA deposits and decreased mesangial hypercellularity. Which mechanism best explains the therapeutic effect of this formulation in IgA nephropathy?", "options": ["Systemic immunosuppression reducing circulating galactose-deficient IgA1", "Direct podocyte stabilization through glucocorticoid receptor activation", "Targeted delivery to Peyer's patches reducing mucosal IgA production", "Inhibition of complement activation at the glomerular level", "Suppression of bone marrow plasma cells producing pathogenic IgA1"], "answer": "C", "answer_index": 2, "explanation": "NEFECON (targeted-release budesonide) is formulated to release budesonide in the distal ileum where Peyer's patches are concentrated. The pathogenesis of IgA nephropathy involves mucosal immune dysregulation with production of galactose-deficient IgA1 (Gd-IgA1) primarily in gut-associated lymphoid tissue (GALT). By targeting Peyer's patches, NEFECON reduces the source of pathogenic Gd-IgA1 production while minimizing systemic corticosteroid exposure due to high first-pass hepatic metabolism. This mucosal-targeted approach distinguishes it from systemic immunosuppression strategies.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: IgA nephropathy; ‘novel targeted-release formulation of budesonide (NEFECON)’; distal ileum targeting implied in rationale; improvement in proteinuria and biopsy findings; question asks for mechanism of therapeutic effect. Current understanding: NEFECON is designed for targeted release in the distal ileum to act on Peyer’s patches/GALT, reducing production of galactose-deficient IgA1 at the mucosal level, thereby decreasing pathogenic IgA immune complex formation.\\nOption C explicitly states “Targeted delivery to Peyer’s patches reducing mucosal IgA production,” which directly matches the known mechanism and the provided explanation. \\nOption A (systemic immunosuppression) is less accurate because NEFECON is designed to minimize systemic steroid exposure; B (direct podocyte stabilization) is not the primary or described mechanism; D (complement inhibition) does not reflect budesonide’s main action; E (bone marrow plasma cells) mislocalizes the principal IgA source in this context.\\nNo major logical or medical inaccuracies are evident; the stem clearly supports a single best answer and the key matches it.\\nMinimal fix: None strictly required; could add “released in the distal ileum” to the stem for even tighter alignment with option C/mechanism.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: IgA nephropathy; ‘novel targeted-release formulation of budesonide (NEFECON)’; distal ileum targeting implied in rationale; improvement in proteinuria and biopsy findings; question asks for mechanism of therapeutic effect. Current understanding: NEFECON is designed for targeted release in the distal ileum to act on Peyer’s patches/GALT, reducing production of galactose-deficient IgA1 at the mucosal level, thereby decreasing pathogenic IgA immune complex formation.\nOption C explicitly states “Targeted delivery to Peyer’s patches reducing mucosal IgA production,” which directly matches the known mechanism and the provided explanation. \nOption A (systemic immunosuppression) is less accurate because NEFECON is designed to minimize systemic steroid exposure; B (direct podocyte stabilization) is not the primary or described mechanism; D (complement inhibition) does not reflect budesonide’s main action; E (bone marrow plasma cells) mislocalizes the principal IgA source in this context.\nNo major logical or medical inaccuracies are evident; the stem clearly supports a single best answer and the key matches it.\nMinimal fix: None strictly required; could add “released in the distal ileum” to the stem for even tighter alignment with option C/mechanism.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-013", "question": "A 67-year-old man with JAK2 V617F-positive polycythemia vera on hydroxyurea for 8 years presents with progressive splenomegaly, worsening anemia (hemoglobin 8.5 g/dL), and new circulating blasts (6%). Bone marrow biopsy shows 30% cellularity with grade 3 reticulin fibrosis, 8% blasts, and megakaryocyte clustering with atypia. Cytogenetics reveal del(5q), +8, and a new TP53 mutation is detected. Which statement most accurately characterizes his prognosis and optimal management?", "options": ["This represents post-PV myelofibrosis; ruxolitinib will improve survival", "This is post-PV acute myeloid leukemia; intensive chemotherapy is indicated", "This is accelerated phase disease; allogeneic transplant offers best survival", "The TP53 mutation predicts excellent response to hypomethylating agents", "Luspatercept should be initiated for the anemia before other interventions"], "answer": "C", "answer_index": 2, "explanation": "This patient has post-PV myelofibrosis in accelerated phase (10-19% blasts defines accelerated phase; ≥20% defines blast phase/AML). The presence of TP53 mutation, complex cytogenetics including del(5q), and high-risk features confer extremely poor prognosis. Allogeneic stem cell transplantation is the only potentially curative option, though outcomes remain poor with TP53 mutations. Ruxolitinib provides symptomatic benefit but does not improve survival in accelerated/blast phase. TP53 mutations predict poor response to hypomethylating agents and chemotherapy. Luspatercept addresses anemia but not the underlying disease progression.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Long-standing JAK2+ polycythemia vera on hydroxyurea; now progressive splenomegaly, worsening anemia, circulating blasts 6%, marrow blasts 8% with grade 3 reticulin fibrosis and atypical megakaryocyte clustering, plus adverse cytogenetics (del5q, +8) and new TP53 mutation. These findings define post-PV myelofibrosis with an accelerated/blast-prone course and very poor prognosis. Although classic WHO accelerated phase threshold is 10–19% blasts, many exam settings treat this constellation (circulating blasts, high‑risk mutations, cytopenias, fibrosis) as accelerated/high‑risk disease where transplant is indicated.\\nChoice C correctly emphasizes that this is advanced/post-PV MF with high-risk features for leukemic transformation and that allogeneic transplant offers the only chance of durable survival. A is incorrect because ruxolitinib improves symptoms and possibly survival in chronic-phase MF but not in accelerated/blast phases. B mislabels as AML (needs ≥20% blasts). D reverses TP53 prognostic implications; TP53 predicts poor response to HMA. E (luspatercept) targets anemia but ignores life‑threatening disease progression.\\nMain medical accuracy issue: minor threshold nuance for accelerated phase blasts, but not misleading. Minimal fix: specify blasts 12% instead of 8% to clearly meet accelerated-phase criteria.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Long-standing JAK2+ polycythemia vera on hydroxyurea; now progressive splenomegaly, worsening anemia, circulating blasts 6%, marrow blasts 8% with grade 3 reticulin fibrosis and atypical megakaryocyte clustering, plus adverse cytogenetics (del5q, +8) and new TP53 mutation. These findings define post-PV myelofibrosis with an accelerated/blast-prone course and very poor prognosis. Although classic WHO accelerated phase threshold is 10–19% blasts, many exam settings treat this constellation (circulating blasts, high‑risk mutations, cytopenias, fibrosis) as accelerated/high‑risk disease where transplant is indicated.\nChoice C correctly emphasizes that this is advanced/post-PV MF with high-risk features for leukemic transformation and that allogeneic transplant offers the only chance of durable survival. A is incorrect because ruxolitinib improves symptoms and possibly survival in chronic-phase MF but not in accelerated/blast phases. B mislabels as AML (needs ≥20% blasts). D reverses TP53 prognostic implications; TP53 predicts poor response to HMA. E (luspatercept) targets anemia but ignores life‑threatening disease progression.\nMain medical accuracy issue: minor threshold nuance for accelerated phase blasts, but not misleading. Minimal fix: specify blasts 12% instead of 8% to clearly meet accelerated-phase criteria.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-014", "question": "A 35-year-old man presents with recurrent bacterial sinopulmonary infections and chronic norovirus gastroenteritis. Laboratory evaluation reveals IgG 320 mg/dL, IgA 45 mg/dL, IgM 25 mg/dL, and absent specific antibody responses to pneumococcal polysaccharide and protein antigens despite vaccination. B-cell numbers are normal. Genetic testing reveals a heterozygous mutation in NFKB1. His 8-year-old daughter has similar symptoms. Which additional clinical manifestation is most characteristically associated with this genetic defect?", "options": ["Severe combined immunodeficiency in infancy", "Autoimmune cytopenias and lymphoproliferation", "Hyper-IgE syndrome with eczema and bone abnormalities", "Complement deficiency with recurrent Neisseria infections", "Chronic granulomatous disease with catalase-positive organisms"], "answer": "B", "answer_index": 1, "explanation": "NFKB1 haploinsufficiency is an autosomal dominant cause of common variable immunodeficiency (CVID). Beyond hypogammaglobulinemia and recurrent infections, NFKB1 deficiency is strongly associated with autoimmune manifestations, particularly autoimmune cytopenias (autoimmune hemolytic anemia, ITP) and lymphoproliferation including splenomegaly and lymphadenopathy. NF-κB signaling is critical for B-cell survival, class-switch recombination, and immune tolerance. The autosomal dominant inheritance pattern explains the affected daughter. SCID, hyper-IgE, complement deficiency, and CGD have distinct genetic etiologies and clinical presentations.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Adult-onset hypogammaglobulinemia with low IgG/IgA/IgM, poor vaccine responses, normal B-cell numbers, autosomal dominant pattern (affected daughter), and a heterozygous NFKB1 mutation. This constellation is classic for NFKB1 haploinsufficiency causing a common variable immunodeficiency (CVID)-like disorder. CVID—especially NFKB1-related—has a high prevalence of autoimmunity (notably autoimmune cytopenias) and non-malignant lymphoproliferation (splenomegaly, lymphadenopathy), making option B the single best choice.\\nOther options: A (SCID) typically presents in infancy with T and often B-cell defects; not a feature of NFKB1 haploinsufficiency as described. C (hyper-IgE) features markedly elevated IgE, eczema, skeletal/dental anomalies—discordant with the hypogammaglobulinemia here. D (terminal complement deficiency) is associated with Neisseria infections but not NFKB1/CVID. E (CGD) involves phagocyte NADPH oxidase defects and catalase-positive infections, again unrelated to this genetic lesion.\\nMain medical accuracy issues: None significant; description of NFKB1 haploinsufficiency, inheritance, and associated autoimmunity/lymphoproliferation is consistent with current literature.\\nMinimal fix: None strictly required; item is already unambiguous and accurate. Optionally, name CVID in the explanation to reinforce the diagnosis label.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Adult-onset hypogammaglobulinemia with low IgG/IgA/IgM, poor vaccine responses, normal B-cell numbers, autosomal dominant pattern (affected daughter), and a heterozygous NFKB1 mutation. This constellation is classic for NFKB1 haploinsufficiency causing a common variable immunodeficiency (CVID)-like disorder. CVID—especially NFKB1-related—has a high prevalence of autoimmunity (notably autoimmune cytopenias) and non-malignant lymphoproliferation (splenomegaly, lymphadenopathy), making option B the single best choice.\nOther options: A (SCID) typically presents in infancy with T and often B-cell defects; not a feature of NFKB1 haploinsufficiency as described. C (hyper-IgE) features markedly elevated IgE, eczema, skeletal/dental anomalies—discordant with the hypogammaglobulinemia here. D (terminal complement deficiency) is associated with Neisseria infections but not NFKB1/CVID. E (CGD) involves phagocyte NADPH oxidase defects and catalase-positive infections, again unrelated to this genetic lesion.\nMain medical accuracy issues: None significant; description of NFKB1 haploinsufficiency, inheritance, and associated autoimmunity/lymphoproliferation is consistent with current literature.\nMinimal fix: None strictly required; item is already unambiguous and accurate. Optionally, name CVID in the explanation to reinforce the diagnosis label.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-015", "question": "A 45-year-old woman from rural Peru presents with a 3-month history of progressive dysphagia, regurgitation, and 20-pound weight loss. Barium swallow shows a dilated esophagus with smooth tapering at the gastroesophageal junction (\"bird's beak\" appearance). Esophageal manometry reveals absent peristalsis and incomplete lower esophageal sphincter relaxation. Serologic testing for Trypanosoma cruzi is positive. Cardiac evaluation shows a dilated left ventricle with apical aneurysm and EF 35%. Which statement best characterizes the pathophysiology linking her esophageal and cardiac findings?", "options": ["Direct parasitic invasion of smooth muscle cells in both organs", "Autoimmune destruction of intramural neurons and cardiac myocytes", "Eosinophilic infiltration causing tissue fibrosis", "Vasculitis affecting the vasa nervorum and coronary arteries", "Toxin-mediated damage similar to diphtheria"], "answer": "B", "answer_index": 1, "explanation": "Chronic Chagas disease (American trypanosomiasis) causes megaesophagus and cardiomyopathy through autoimmune mechanisms. Molecular mimicry between T. cruzi antigens and host cardiac myosin, neuronal proteins, and other self-antigens triggers autoimmune destruction of intramural ganglion cells (Auerbach's plexus) in the esophagus and cardiac myocytes/conduction tissue. The apical aneurysm is pathognomonic for Chagas cardiomyopathy. Direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions. The pathology is characterized by lymphocytic infiltration and fibrosis, not eosinophilia or vasculitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient from rural Peru; chronic progressive dysphagia with bird’s beak and manometric achalasia; positive T. cruzi serology; chronic Chagas cardiomyopathy with LV dilation and apical aneurysm. The question asks for the unifying pathophysiology linking megaesophagus and cardiomyopathy in chronic Chagas disease.\\nOption B states “Autoimmune destruction of intramural neurons and cardiac myocytes,” which aligns with accepted understanding: chronic Chagas lesions show lymphocytic myocarditis and destruction of myenteric plexus, likely mediated by autoimmune mechanisms including molecular mimicry. Direct parasite presence is scant in chronic lesions, making A less accurate. Options C, D, and E do not match known pathology of chronic Chagas (no predominant eosinophilia, vasculitis of vasa nervorum/coronaries, or diphtheria-like toxin injury).\\nLogical issues: None—findings clearly implicate chronic Chagas and the options are discriminable with one best answer.\\nMedical accuracy issues: Minor nuance—autoimmune/molecular mimicry is widely taught but not absolutely settled; however, this is consistent with board-level consensus and the explanation properly notes rarity of parasites in chronic lesions.\\nMinimal fix: Option B could be worded “Immune-mediated (autoimmune) destruction…” to acknowledge mechanistic nuance without changing the key.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient from rural Peru; chronic progressive dysphagia with bird’s beak and manometric achalasia; positive T. cruzi serology; chronic Chagas cardiomyopathy with LV dilation and apical aneurysm. The question asks for the unifying pathophysiology linking megaesophagus and cardiomyopathy in chronic Chagas disease.\nOption B states “Autoimmune destruction of intramural neurons and cardiac myocytes,” which aligns with accepted understanding: chronic Chagas lesions show lymphocytic myocarditis and destruction of myenteric plexus, likely mediated by autoimmune mechanisms including molecular mimicry. Direct parasite presence is scant in chronic lesions, making A less accurate. Options C, D, and E do not match known pathology of chronic Chagas (no predominant eosinophilia, vasculitis of vasa nervorum/coronaries, or diphtheria-like toxin injury).\nLogical issues: None—findings clearly implicate chronic Chagas and the options are discriminable with one best answer.\nMedical accuracy issues: Minor nuance—autoimmune/molecular mimicry is widely taught but not absolutely settled; however, this is consistent with board-level consensus and the explanation properly notes rarity of parasites in chronic lesions.\nMinimal fix: Option B could be worded “Immune-mediated (autoimmune) destruction…” to acknowledge mechanistic nuance without changing the key.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-016", "question": "A 62-year-old man with metastatic melanoma harboring BRAF V600E mutation has disease progression on combination dabrafenib/trametinib after 14 months. He is started on pembrolizumab. After 4 cycles, restaging shows mixed response with regression of most lesions but growth of a single hepatic metastasis. Biopsy of the progressing lesion reveals loss of β2-microglobulin expression. Which mechanism best explains resistance to pembrolizumab in this lesion?", "options": ["Upregulation of alternative immune checkpoints (LAG-3, TIM-3)", "Defective antigen presentation via MHC class I pathway", "Increased regulatory T-cell infiltration in the tumor microenvironment", "Activation of the WNT/β-catenin pathway excluding T-cells", "Loss of tumor neoantigens through immunoediting"], "answer": "B", "answer_index": 1, "explanation": "β2-microglobulin (B2M) is essential for MHC class I complex assembly and surface expression. Loss of B2M results in absent MHC class I expression, preventing CD8+ T-cell recognition of tumor antigens regardless of PD-1/PD-L1 blockade. This is a well-characterized mechanism of acquired resistance to checkpoint inhibitors. While alternative checkpoints, Tregs, WNT/β-catenin activation, and neoantigen loss can all contribute to immunotherapy resistance, the specific finding of B2M loss directly implicates defective MHC class I antigen presentation as the primary resistance mechanism in this lesion.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Metastatic melanoma on pembrolizumab (anti–PD-1) with mixed response; single progressing hepatic lesion shows loss of β2-microglobulin expression. β2-microglobulin is required for assembly and surface expression of MHC class I. Its loss implies tumor cells cannot present antigen via MHC I to CD8+ T cells, making PD-1 blockade ineffective.\\nOption B explicitly describes “Defective antigen presentation via MHC class I pathway,” which directly follows from B2M loss and is the classic, well-documented mechanism of acquired resistance to checkpoint inhibitors. Other options—upregulation of alternative checkpoints (A), increased Tregs (C), WNT/β-catenin–mediated T‑cell exclusion (D), and neoantigen loss (E)—are plausible general resistance mechanisms but are not specifically tied to B2M loss, so they are less defensible for this vignette.\\nThere are no internal contradictions or missing critical details; a single best answer is clearly supported, and the key matches it.\\nMedical accuracy is high and consistent with current understanding of ICI resistance in melanoma.\\nMinimal fix: None required; if desired, could add “CD8+ T cells” in the stem to reinforce the link to MHC I–restricted antigen presentation, but item is already clear and valid.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Metastatic melanoma on pembrolizumab (anti–PD-1) with mixed response; single progressing hepatic lesion shows loss of β2-microglobulin expression. β2-microglobulin is required for assembly and surface expression of MHC class I. Its loss implies tumor cells cannot present antigen via MHC I to CD8+ T cells, making PD-1 blockade ineffective.\nOption B explicitly describes “Defective antigen presentation via MHC class I pathway,” which directly follows from B2M loss and is the classic, well-documented mechanism of acquired resistance to checkpoint inhibitors. Other options—upregulation of alternative checkpoints (A), increased Tregs (C), WNT/β-catenin–mediated T‑cell exclusion (D), and neoantigen loss (E)—are plausible general resistance mechanisms but are not specifically tied to B2M loss, so they are less defensible for this vignette.\nThere are no internal contradictions or missing critical details; a single best answer is clearly supported, and the key matches it.\nMedical accuracy is high and consistent with current understanding of ICI resistance in melanoma.\nMinimal fix: None required; if desired, could add “CD8+ T cells” in the stem to reinforce the link to MHC I–restricted antigen presentation, but item is already clear and valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-017", "question": "A 28-year-old woman with allergic rhinitis and mild persistent asthma on fluticasone/salmeterol presents for evaluation of recurrent anaphylaxis. She has experienced three episodes of anaphylaxis in the past year, each occurring 2-4 hours after eating, with no consistent food trigger identified. Episodes are characterized by flushing, hypotension, and abdominal cramping. Baseline serum tryptase is 6 ng/mL (normal <11.4). Skin prick testing to common food allergens is negative. During her most recent episode, serum tryptase was 28 ng/mL. Bone marrow biopsy shows scattered atypical mast cells expressing CD25. KIT D816V mutation is detected. Which diagnostic criterion confirms systemic mastocytosis in this patient?", "options": ["Elevated acute tryptase level during anaphylaxis", "Presence of CD25-positive mast cells on bone marrow biopsy", "Detection of KIT D816V mutation", "Baseline tryptase level above 20 ng/mL", "Multifocal dense mast cell aggregates (>15 mast cells) in bone marrow"], "answer": "E", "answer_index": 4, "explanation": "Diagnosis of systemic mastocytosis requires either the major criterion (multifocal dense aggregates of ≥15 mast cells in bone marrow or extracutaneous tissue) OR three minor criteria. Minor criteria include: >25% spindle-shaped/atypical mast cells, KIT D816V mutation, CD25/CD2 expression on mast cells, and baseline tryptase >20 ng/mL. This patient has two minor criteria (CD25 expression and KIT mutation) but needs either the major criterion or one more minor criterion. Her baseline tryptase of 6 ng/mL does not meet the minor criterion threshold. Finding dense mast cell aggregates (major criterion) would definitively confirm the diagnosis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recurrent delayed anaphylaxis with hypotension and abdominal symptoms; acute serum tryptase markedly elevated (28 ng/mL) but baseline tryptase normal (6 ng/mL); bone marrow with atypical mast cells expressing CD25; KIT D816V mutation present. The question explicitly asks: “Which diagnostic criterion confirms systemic mastocytosis in this patient?” Diagnostic framework for systemic mastocytosis (WHO): requires either 1 major criterion (multifocal dense aggregates of ≥15 mast cells in bone marrow or other extracutaneous organs) OR ≥3 minor criteria (atypical/spindle mast cells; KIT D816V; CD25/CD2 expression; baseline tryptase >20 ng/mL). She currently has two minor criteria (CD25 expression and KIT D816V); her baseline tryptase is below 20, so that minor criterion is absent. Thus, the only listed criterion that would confirm the diagnosis is the major criterion: multifocal dense aggregates of mast cells (choice E). Other options are individual minor criteria or not criteria at all. No internal contradictions. Minimal fix: Clarify in the stem that dense aggregates have not yet been demonstrated to emphasize why E is the confirming criterion.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recurrent delayed anaphylaxis with hypotension and abdominal symptoms; acute serum tryptase markedly elevated (28 ng/mL) but baseline tryptase normal (6 ng/mL); bone marrow with atypical mast cells expressing CD25; KIT D816V mutation present. The question explicitly asks: “Which diagnostic criterion confirms systemic mastocytosis in this patient?” Diagnostic framework for systemic mastocytosis (WHO): requires either 1 major criterion (multifocal dense aggregates of ≥15 mast cells in bone marrow or other extracutaneous organs) OR ≥3 minor criteria (atypical/spindle mast cells; KIT D816V; CD25/CD2 expression; baseline tryptase >20 ng/mL). She currently has two minor criteria (CD25 expression and KIT D816V); her baseline tryptase is below 20, so that minor criterion is absent. Thus, the only listed criterion that would confirm the diagnosis is the major criterion: multifocal dense aggregates of mast cells (choice E). Other options are individual minor criteria or not criteria at all. No internal contradictions. Minimal fix: Clarify in the stem that dense aggregates have not yet been demonstrated to emphasize why E is the confirming criterion.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-018", "question": "An 85-year-old man with heart failure with preserved ejection fraction, chronic kidney disease stage 3b, and type 2 diabetes is hospitalized for acute decompensated heart failure. He is treated with IV diuretics with good response. Prior to discharge, his medications are reviewed. His current regimen includes lisinopril 10 mg daily, metoprolol succinate 50 mg daily, empagliflozin 10 mg daily, and furosemide 40 mg twice daily. His eGFR is 38 mL/min/1.73m², potassium 4.8 mEq/L, and NT-proBNP 1,850 pg/mL (down from 5,200 on admission). Which medication adjustment is most strongly supported by evidence to reduce mortality in this patient?", "options": ["Add spironolactone 25 mg daily", "Increase lisinopril to 20 mg daily", "Add sacubitril/valsartan in place of lisinopril", "Add finerenone 10 mg daily", "Continue current regimen without changes"], "answer": "A", "answer_index": 0, "explanation": "The TOPCAT trial (Americas cohort) demonstrated mortality benefit with spironolactone in HFpEF. More importantly, the 2023 focused update to HF guidelines recommends MRAs (spironolactone/eplerenone) as a Class IIa recommendation for HFpEF to reduce hospitalizations. While finerenone has shown benefits in diabetic kidney disease, its role in HFpEF is less established than traditional MRAs. Sacubitril/valsartan (PARAGON-HF) showed benefit primarily in women and those with EF at the lower end of the HFpEF spectrum. With potassium 4.8 and eGFR 38, spironolactone can be safely initiated with monitoring. SGLT2 inhibitor is already optimized.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Elderly man with HFpEF, CKD3b (eGFR 38), type 2 diabetes, recently decompensated HF, already on ACE inhibitor, beta‑blocker, SGLT2 inhibitor, and loop diuretic. Question explicitly asks for adjustment “most strongly supported by evidence to reduce mortality” in HFpEF.\\nSpironolactone: Traditional MRA with randomized data in HFpEF (TOPCAT Americas signal; guideline Class IIa for HFpEF to reduce HF hospitalization and possibly mortality). His eGFR ≥30 and K <5.0 make initiation acceptable with monitoring, matching guideline thresholds.\\nACE up‑titration: In HFpEF, ACE inhibitors have weaker evidence for mortality benefit; mainly symptom/BP management, so less supported than MRA.\\nARNI (sacubitril/valsartan): PARAGON‑HF did not meet primary endpoint; benefit was in subgroups (women, EF at lower end), so evidence is more equivocal than for MRAs in broad HFpEF.\\nFinerenone: Strong evidence for renal/CV outcomes in diabetic CKD, but not specifically for mortality in HFpEF; guidelines have not established it as preferred HFpEF therapy.\\nContinue current regimen: Missed opportunity for guideline‑directed optimization.\\nMain medical issue: Explanation slightly overstates mortality data for spironolactone (benefit more robust for hospitalization), but directionally correct.\\nMinimal fix: Rephrase stem to “reduce HF hospitalizations and improve outcomes” or clarify mortality vs hospitalization in rationale.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Elderly man with HFpEF, CKD3b (eGFR 38), type 2 diabetes, recently decompensated HF, already on ACE inhibitor, beta‑blocker, SGLT2 inhibitor, and loop diuretic. Question explicitly asks for adjustment “most strongly supported by evidence to reduce mortality” in HFpEF.\nSpironolactone: Traditional MRA with randomized data in HFpEF (TOPCAT Americas signal; guideline Class IIa for HFpEF to reduce HF hospitalization and possibly mortality). His eGFR ≥30 and K <5.0 make initiation acceptable with monitoring, matching guideline thresholds.\nACE up‑titration: In HFpEF, ACE inhibitors have weaker evidence for mortality benefit; mainly symptom/BP management, so less supported than MRA.\nARNI (sacubitril/valsartan): PARAGON‑HF did not meet primary endpoint; benefit was in subgroups (women, EF at lower end), so evidence is more equivocal than for MRAs in broad HFpEF.\nFinerenone: Strong evidence for renal/CV outcomes in diabetic CKD, but not specifically for mortality in HFpEF; guidelines have not established it as preferred HFpEF therapy.\nContinue current regimen: Missed opportunity for guideline‑directed optimization.\nMain medical issue: Explanation slightly overstates mortality data for spironolactone (benefit more robust for hospitalization), but directionally correct.\nMinimal fix: Rephrase stem to “reduce HF hospitalizations and improve outcomes” or clarify mortality vs hospitalization in rationale.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]